⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL543581 | 0.80 | — | — | |
| SCHEMBL226311 | 0.77 | — | — | |
| SCHEMBL117832 | 0.77 | — | — | |
| SCHEMBL4300520 | 0.77 | DGAT1 (0.46) | — | |
| SCHEMBL135961 | 0.77 | — | — | |
| SCHEMBL27622606 | 0.77 | — | — | |
| SCHEMBL9345959 | 0.77 | DGAT1 (0.46) | — | |
| SCHEMBL3205620 | 0.76 | ALDH1A1 (0.39) | — | |
| SCHEMBL28035795 | 0.74 | — | — | |
| SCHEMBL31058002 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114591223-B | Beta-lactamase inhibitor compounds | 恩塔西斯治疗有限公司 | 2025-01-24 | — | — | CN | disclosed |
| US-20240425505-A1 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2024-12-26 | — | — | US | disclosed |
| US-12110290-B2 | Triazolopyridinyl compounds as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-10-08 | — | — | US | disclosed |
| EP-4364737-A2 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2024-05-08 | — | — | EP | disclosed |
| EP-4229056-B1 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2024-04-10 | — | — | EP | disclosed |
| US-20240109888-A1 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2024-04-04 | — | — | US | disclosed |
| US-11767322-B2 | Triazolopyridinyl compounds as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-09-26 | — | — | US | disclosed |
| CN-116802181-A | Triazolopyridine compounds as kinase inhibitors | 百时美施贵宝公司 | 2023-09-22 | — | — | CN | disclosed |
| EP-4229056-A1 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-3512851-B1 | BETA-LACTAMASE INHIBITOR COMPOUNDS | ENTASIS THERAPEUTICS LTD (GB) | 2022-07-06 | — | — | EP | disclosed |
| EP-3512851-A1 | BETA-LACTAMASE INHIBITOR COMPOUNDS | Entasis Therapeutics Limited (GB) | 2019-07-24 | — | — | EP | disclosed |
| US-20190202832-A1 | BETA-LACTAMASE INHIBITOR COMPOUNDS | ENTASIS THERAPEUTICS LIMITED (GB) | 2019-07-04 | — | — | US | disclosed |
| WO-2018053215-A1 | BETA-LACTAMASE INHIBITOR COMPOUNDS | ENTASIS THERAPEUTICS LIMITED (GB) | 2018-03-22 | — | — | WO | disclosed |
| US-8450520-B2 | Process for preparation of 2-fluoroacrylic esters | CENTRAL GLASS COMPANY, LIMITED (JP) | 2013-05-28 | — | — | US | disclosed |
| US-8450520-B2 | Process for preparation of 2-fluoroacrylic esters | CENTRAL GLASS COMPANY, LIMITED (JP) | 2013-05-28 | — | — | US | disclosed |
| US-8450520-B2 | Process for preparation of 2-fluoroacrylic esters | CENTRAL GLASS COMPANY, LIMITED (JP) | 2013-05-28 | — | — | US | disclosed |
| EP-2444389-A1 | PROCESS FOR PREPARATION OF 2-FLUOROACRYLIC ESTERS | Central Glass Company, Limited (JP) | 2012-04-25 | — | — | EP | disclosed |
| US-20120059187-A1 | Process for Preparation of 2-Fluoroacrylic Esters | CENTRAL GLASS COMPANY, LIMITED (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20120059187-A1 | Process for Preparation of 2-Fluoroacrylic Esters | CENTRAL GLASS COMPANY, LIMITED (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20120059187-A1 | Process for Preparation of 2-Fluoroacrylic Esters | CENTRAL GLASS COMPANY, LIMITED (JP) | 2012-03-08 | — | — | US | disclosed |